Cytokinetics should hear back from the FDA ... In the company's third-quarter results update, chief executive Robert Blum said that aficamten has a "next-in-class safety and efficacy profile ...

Cytokinetics' chief executive, Robert Blum, said the new deal with Royalty Pharma “reinforces our shared conviction in the value of our cardiac myosin-focused pipeline of drug candidates.” ...

Notable insider trades include Malik Fady Ibraham, EVP Research & Development at Cytokinetics, Inc. (CYTK), who sold 7300 shares on Dec 10 ’24, at $50.64 each, totaling $0.37 million. On Dec 02 ’24, ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

After hours: January 17 at 6:11:16 PM EST ...

Aficamten is under clinical development by Cytokinetics and currently in Pre-Registration for Hypertrophic Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Hypertrophic ...

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors. The Full BIO Board of Directors is comprised of all ...